THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

JUN 1 4 2004

Thomas Gruber

Appl. No.:

10/772,647

Conf. No.:

5813

Filed:

February 4, 2004

Title:

PHARMACEUTICAL FORMULATION CONTAINING DYE

Art Unit:

1615

Examiner:

Unknown

Docket No.:

111458-004

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, be made during the course of examination of the above-identified application for United States patent. Pursuant to the Official Gazette Notice dated August 5, 2003, copies of the cited U.S. patents and patent applications are not included as this application was filed after June 30, 2003. However, copies of all other cited references are included with this form.

U.S. PATENT DOCUMENTS

Document No.	<u>Date</u>	<u>Inventor</u>
3,980,766	September 14, 1976	Shaw et al.
4,769,372	September 6, 1988	Kreek
4,785,000	November 15, 1988	Kreek et al.
5,266,331	November 30, 1993	Oshlack et al.
5,472,943	December 5, 1995	Crain et al.
5,508,042	April 16, 1996	Oshlack et al.
5,549,912	August 27, 1996	Oshlack et al.
5,656,295	August 12, 1997	Oshlack et al.
6,228,863	May 8, 2001	Palermo et al.
6,245,357	June 12, 2001	Edgren et al.

FOREIGN PATENT DOCUMENTS

Document No.

<u>Date</u>

Country

WO 99/32119

July 1, 1999

PCT

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY

Adam H. Masia Reg. No.35,602 P.O. Box 1135

Chicago, Illinois 60690-1135

Phone: (312) 807-4284

Dated: June 8, 2004



INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

PTO Form 1449

Atty Docket No.	Application No.	
111458	10/772,647	
Applicant		
Thomas Gruber		
Filing Date	Group	
February 4, 2004	Group 1615	

		U.S. PATENT	DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
	3,980,766	September 14, 1976	Shaw et al.			
	4,769,372	September 6, 1988	Kreek			
	4,785,000	November 15, 1988	Kreek et al.			
	5,266,331	November 30, 1993	Oshlack et al.			
	5,472,943	December 5, 1995	Crain et al.			
	5,508,042	April 16, 1996	Oshlack et al.		·.	<u>.</u>
	5,549,912	August 27, 1996	Oshlack et al.			
	5,656,295	August 12, 1997	Oshlack et al.			
	6,228,863	May 8, 2001	Palermo et al.			
	6,245,357	June 12, 2001	Edgren et al.			

FOREIGN PATENT DOCUMENTS							
Examiner's Document Publication Translation						lation	
Initials	Number	Date	Country	Class	Subclass	Yes	No
	WO 99/32119	July 1, 1999	PCT				

Examiner's Initials	 OTHER DOCUMENTS (1	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
		·					
	:						
·							

Examiner:	Date Considered:

602930/D/1 Page 1

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<u> </u>				STW		
TRA	TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) Docket No. 111458-004					
In Re A	pplication Of: 7	Thomas Gruber JUN 1 4 2004				
1	Serial No.	Filing Cate February 4, 2007	Examiner Unknown	Group Art Unit 1615		
Title:	PHARMACEUTI	CAL FORMULATION CONTAINI	NG DYE	L		
				and the same of th		
		Commission P.O. E	ess to: ner for Patents 3ox 1450 VA 22313-1450			
		37 CFI	R 1.97(b)			
1. 🛚	The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
		37 CF	R 1.97(c)			
2.	CFR 1.97(b), pr Final Action und	Disclosure Statement submitted hovided that the Information Discloder 37 CFR 1.113, a Notice of As prosecution in the application, and	sure Statement is filed befo Allowance under 37 CFR	ore the mailing date of a 1.311, or an Action that		
	☐ the staten	nent specified in 37 CFR 1.97(e);				
		OR				
	☐ the fee se	et forth in 37 CFR 1.17(p).				
	·					

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 111458-004		
In Re Application: T	homas Gruber JUN 1 4 2004				
Serial No.	Filing Date		Examiner	Group Art Unit	
10/772,647	February 4, 200 EMARK		Unknown	1615	
PHARMACEUTIO	CAL FORMULATION CONTAIN	NIN	IG DYE		
	•		t of Fee to pay the fee set forth in 37 CFR 1.1	17(p))	
as described below. Charge the amount of Credit any overpayment. Charge any additional fee required. Certificate of Transmission by Facsimile* Certificate of Mailing by First Class Mail I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F: (Date) Certificate of Mailing by First Class Mail I certify that this document and fee is being deposited on June 8, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.					
Signature Signature of Person Mailing Correspondence					
Renee Street					
Typed or Printed Name of Person Signing Certificate Typed or Printed Name of Person Mailing Certificate					
deposit account.		1	Dated: June 8, 2004		